<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2024.1353780</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>An interpretable clinical ultrasound-radiomics combined model for diagnosis of stage I cervical cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Xianyue</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2620077"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Chuanfen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2615038"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Nian</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2620725"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qin</surname>
<given-names>Xiachuan</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1970805"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Xiaoling</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1964611"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Chaoxue</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1692747"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University</institution>, <addr-line>Hefei, Anhui</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Ultrasound, Anhui Provincial Maternity and Child Health Hospital</institution>, <addr-line>Hefei, Anhui</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Ultrasound, Nanchong Central Hospital (Beijing Anzhen Hospital Nanchong Hospital), The Second Clinical Medical College, North Sichuan Medical College (University)</institution>, <addr-line>Nanchong, Sichuan</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Chengquan Zhao, University of Pittsburgh, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Thomas Samuel Ram, Christian Medical College and Hospital, India</p>
<p>Sean Benson, Amsterdam University Medical Center, Netherlands</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Chaoxue Zhang, <email xlink:href="mailto:zcxay@163.com">zcxay@163.com</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>14</volume>
<elocation-id>1353780</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>12</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Yang, Gao, Sun, Qin, Liu and Zhang</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Yang, Gao, Sun, Qin, Liu and Zhang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>The purpose of this retrospective study was to establish a combined model based on ultrasound (US)-radiomics and clinical factors to predict patients with stage I cervical cancer (CC) before surgery.</p>
</sec>
<sec>
<title>Materials and methods</title>
<p>A total of 209 CC patients who had cervical lesions found by transvaginal sonography (TVS) from the First Affiliated Hospital of Anhui Medical University were retrospectively reviewed, patients were divided into the training set (n = 146) and internal validation set (n = 63), and 52 CC patients from Anhui Provincial Maternity and Child Health Hospital and Nanchong Central Hospital were taken as the external validation set. The clinical independent predictors were selected by univariate and multivariate logistic regression analyses. US-radiomics features were extracted from US images. After selecting the most significant features by univariate analysis, Spearman&#x2019;s correlation analysis, and the least absolute shrinkage and selection operator (LASSO) algorithm, six machine learning (ML) algorithms were used to build the radiomics model. Next, the ability of the clinical, US-radiomics, and clinical US-radiomics combined model was compared to diagnose stage I CC. Finally, the Shapley additive explanations (SHAP) method was used to explain the contribution of each feature.</p>
</sec>
<sec>
<title>Results</title>
<p>Long diameter of the cervical lesion (L) and squamous cell carcinoma-associated antigen (SCCa) were independent clinical predictors of stage I CC. The eXtreme Gradient Boosting (Xgboost) model performed the best among the six ML radiomics models, with area under the curve (AUC) values in the training, internal validation, and external validation sets being 0.778, 0.751, and 0.751, respectively. In the final three models, the combined model based on clinical features and rad-score showed good discriminative power, with AUC values in the training, internal validation, and external validation sets being 0.837, 0.828, and 0.839, respectively. The decision curve analysis validated the clinical utility of the combined nomogram. The SHAP algorithm illustrates the contribution of each feature in the combined model.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>We established an interpretable combined model to predict stage I CC. This non-invasive prediction method may be used for the preoperative identification of patients with stage I CC.</p>
</sec>
</abstract>
<kwd-group>
<kwd>cervical cancer</kwd>
<kwd>ultrasound</kwd>
<kwd>machine learning</kwd>
<kwd>radiomics</kwd>
<kwd>Shapley additive explanations</kwd>
</kwd-group>
<counts>
<fig-count count="6"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="28"/>
<page-count count="10"/>
<word-count count="4243"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Gynecological Oncology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Cervical cancer (CC) is the fourth most common cancer in women worldwide, following breast, colorectal, and lung cancers (<xref ref-type="bibr" rid="B1">1</xref>), and is one of the most common gynecological malignancies (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). Approximately 570,000 new cases of CC and 311,000 deaths occurred in 2018, and China is among the countries with the greatest burden of CC (<xref ref-type="bibr" rid="B4">4</xref>). Currently, the most common CC stage is based on the International Federation of Gynecology and Obstetrics (FIGO) 2018 system. It is divided into four stages, among which stage I refers to carcinoma strictly confined to the cervix uteri (extension to the corpus should be disregarded) (<xref ref-type="bibr" rid="B5">5</xref>), which belongs to early-stage CC, with a good prognosis and 5-year survival rate of approximately 90%, and it is only approximately 30% of them with lymph node metastasis (LNM) (<xref ref-type="bibr" rid="B6">6</xref>). Therefore, the early diagnosis of CC is particularly important. Ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) are all routinely used for CC examinations, but because the imaging pattern has inherent limitations, based on the traditional visual assessment, imaging technology cannot identify the grayscale images, which beyond the scope of human eye recognition, in disease diagnosis and treatment value is limited, hence the need more advanced tools to improve the existing imaging technology.</p>
<p>In recent years, radiomics has gradually become a research hotspot, which is a widely used and high-throughput method for medical imaging now (<xref ref-type="bibr" rid="B7">7</xref>). Using radiomics methods can extract quantitative imaging features based on intensity, shape, size volume texture features, etc. The feature redundancy, dimensionality reduction, pre-processing, and machine learning (ML)-based classification combining the extracted features can establish robust and clinically relevant models (<xref ref-type="bibr" rid="B8">8</xref>&#x2013;<xref ref-type="bibr" rid="B10">10</xref>). In recent years, radiomics has been reported to achieve higher precision in the diagnosis, staging, and prognosis of many tumors (<xref ref-type="bibr" rid="B11">11</xref>&#x2013;<xref ref-type="bibr" rid="B14">14</xref>). The standard ML consisting of artificial intelligence is a black-box prediction that is difficult to interpret by clinicians. Due to its ability to interpret and visualize the predictions of a model and to illustrate the contribution of each feature in the model, the Shapley additive explanations (SHAP) algorithm is currently the most recommended for model interpretation. The SHAP values can reveal the individual contribution of each feature to the model output of each observer (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>Studies have shown that radiomics features extracted from MRI or PET/CT images can be used to predict lymph node status (LNS) (<xref ref-type="bibr" rid="B17">17</xref>), tumor stage (<xref ref-type="bibr" rid="B18">18</xref>), histological subtype (<xref ref-type="bibr" rid="B19">19</xref>), and outcomes of neoadjuvant chemoradiation in patients with CC (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). It has also been shown that the radiomics features extracted from US images can be used to predict preoperative LNS in early-stage CC patients (<xref ref-type="bibr" rid="B22">22</xref>). However, to the best of our knowledge, no studies have reported the use of US-radiomics and SHAP for explaining and visualizing the diagnosis of CC staging. Therefore, this study aims to build and validate an interpretable clinical US-radiomics combined model for personalized non-invasive assessment for the detection of stage I CC.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and method</title>
<sec id="s2_1">
<label>2.1</label>
<title>Patients</title>
<p>This study was approved by the Institutional Review Committee of the First Affiliated Hospital of Anhui Medical University (approval number PJ2023&#x2013;07-11). The requirement for informed consent was waived because of the retrospective study design and use of known data. By searching the electronic medical records, CC patients who had cervical lesions found by transvaginal sonography (TVS) in the US Department of the First Affiliated Hospital of Anhui Medical University (Hospital 1) from June 2018 to September 2023 and CC patients of Anhui Provincial Maternity and Child Health Hospital (Hospital 2) and Nanchong Central Hospital (Hospital 3) from January 2018 to October 2023 were analyzed retrospectively.</p>
<p>The inclusion criteria for this study were as follows: 1) pathologically confirmed CC patients who underwent radical hysterectomy, 2) cervical biopsy-confirmed CC patients, and 3) TVS was performed less than 2 weeks before the hysterectomy or biopsy. The exclusion criteria were as follows: 1) chemotherapy or radiotherapy before US examination, 2) patients with a history of other malignancies, 3) the US images were lost or of poor quality, and 4) incomplete clinical information. Ultimately, 209 CC patients were enrolled from Hospital 1, and patients were randomly divided into the training and internal validation sets at a ratio of 7:3. Fifty-two CC patients were enrolled from Hospital 2 and Hospital 3 as the external validation set. The following baseline data were collected: age, SCCa, FIGO stage, histological type, and L by TVS. The study flowchart is shown in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>The flow diagram of the study.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1353780-g001.tif"/>
</fig>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Image acquisition</title>
<p>TVS was performed using a US probe with a frequency of 5&#x2013;9 MHz. The patients&#x2019; bladder must be empty within 10 minutes before the examination; the lithotomy position was taken; a little coupling agent was placed on the top of the probe, a condom was placed, and a little coupling agent was placed on the top again; the probe was slowly inserted into the vagina until the vaginal vault was reached. The gynecological conditions in the machine were selected, and the appropriate depth was adjusted according to the size of the cervical lesion. First, the longitudinal section of the cervix was scanned, and then the transverse section was scanned. Careful and comprehensive observation of the cervical lesion was conducted, 6&#x2013;10 clear and complete cervical lesion US images were collected for each patient, images were stored in a picture archiving and communication system (PACS), and one US image of the maximum section of the lesion was selected finally.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Image segmentation</title>
<p>Cervical US image segmentation was completed by reader 1 (with 7 years of experience in gynecological US examination) and reader 2 (with 15 years of experience in gynecological US examination) using the 3D slicer 5.3.0 software. Regions of interest (ROIs) were manually selected and segmented (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). First, reader 1 and reader 2 delineated ROIs on the cervical US images of 50 randomly selected patients. Two weeks later, reader 1 again delineated the ROIs of these 50 patients. Intra- and inter-class correlation analyses were performed separately to test the consistency of extracted features between Reader 1 and Reader 2. The intra- and inter-class correlation coefficient (ICC) values were greater than 0.75, indicating a good consistency of the extracted features. The segmentation of the remaining cervical US images and the extraction of radiomics features were performed by reader 1 alone.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>The radiomics flowchart of the study.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1353780-g002.tif"/>
</fig>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Radiomics feature extraction and selection</title>
<p>US-radiomics features were extracted using the Pyradiomics 3.0.1 software, which can extract a large number of features from the US images using many engineering algorithms (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). The images were standardized before feature extraction. First, features with ICC &#x2265; 0.75 were included in subsequent analyses. Second, batch effects were removed between Hospital 1 and the external validation set using Combat (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>) (owing to very few cases originating from Hospital 3, the cases from Hospital 2 and Hospital 3 were consolidated as the external validation set). Then, univariate analysis was used for these features, with p &lt; 0.05 features classified as significant correlation variables between stage I and non-stage I CC and included in the subsequent analyses. Again, Spearman&#x2019;s correlation analysis was used to assess the correlation and redundancy of the features. If Spearman&#x2019;s correlation coefficient &#x2265;0.9, the variable was considered redundant and was excluded. Finally, the least absolute shrinkage and selection operator (LASSO) algorithm was applied for further feature selection (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Batch effects were removed between Hospital 1 and the external validation set using Combat.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1353780-g003.tif"/>
</fig>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>Clinical model construction</title>
<p>First, univariate logistic regression analysis was used to analyze the correlation between clinical parameters and the CC stage. The variables with significant correlations (p &lt; 0. 05) were included in the multivariate logistic regression analysis, and then independent predictors significantly associated with the CC stage were identified.</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>US-radiomics model construction</title>
<p>The selected features were trained using six ML algorithms, including linear regression (LR), decision tree (DT), support vector machine (SVM), random forest (RF), K-nearest neighbor (KNN), and eXtreme Gradient Boosting (Xgboost). Fivefold cross-validation (CV) was performed in the training data set to obtain the optimal parameter configuration. The hyperparameters of the six ML algorithms were adjusted using the grid search method and 10-fold CV. The patients in the testing data set were used to evaluate the performance of the model (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>).</p>
</sec>
<sec id="s2_7">
<label>2.7</label>
<title>Statistical analysis</title>
<p>Statistical analyses were performed in the R 4.2.2 analysis platform. Quantitative data with a normal distribution were expressed as mean &#xb1; standard deviation, while quantitative data with a non-normal distribution were expressed as the median (interquartile range). Categorical data were expressed as numbers and percentages. For univariate analysis, the chi-square test, independent sample t-test, or the Mann&#x2013;Whitney U test was used. Correlations were calculated using Spearman&#x2019;s test. The DeLong test was used to compare the performance of the six ML algorithms and three models. The SHAP algorithm was run using the &#x201c;Xgboost&#x201d; and &#x201c;SHAP&#x201d; Python packages. For all tests, p &lt; 0.05 was considered statically significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Patients&#x2019; characteristics</title>
<p>According to the inclusion and exclusion criteria, in this study, 209 CC patients were enrolled from Hospital 1 and divided randomly into the training set (n = 146) and the internal validation set (n = 63). Fifty-two CC patients were enrolled from Hospital 2 and Hospital 3 as the external validation set. The detailed characteristics of these patients in the training, internal validation, and external validation sets are presented in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>. Patients with stage I CC in the training, internal validation, and external validation sets were 51.4%, 50.8%, and 46.2%, respectively.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Detail characteristics in the training, internal validation, and external validation sets.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" colspan="2" align="center">Set (N)</th>
<th valign="middle" colspan="3" align="center">Training set (N = 146)</th>
<th valign="middle" colspan="3" align="center">Internal validation set (N = 63)</th>
<th valign="middle" colspan="3" align="center">External validation set (N = 52)</th>
</tr>
<tr>
<th valign="middle" align="left">Characteristic</th>
<th valign="middle" align="center"/>
<th valign="middle" align="center">C0 (N = 75)</th>
<th valign="middle" align="center">C1 (N = 71)</th>
<th valign="middle" align="center">p</th>
<th valign="middle" align="center">C0 (N = 32)</th>
<th valign="middle" align="center">C1 (N = 31)</th>
<th valign="middle" align="center">p</th>
<th valign="middle" align="center">C0 (N = 24)</th>
<th valign="middle" align="center">C1 (N = 28)</th>
<th valign="middle" align="center">p</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" rowspan="3" align="left">Histological type (n, %)</td>
<td valign="middle" align="center">Adenocarcinoma</td>
<td valign="bottom" align="center">10 (13.3%)</td>
<td valign="bottom" align="center">4 (5.6%)</td>
<td valign="bottom" rowspan="3" align="center">0.177</td>
<td valign="bottom" align="center">7 (21.9%)</td>
<td valign="bottom" align="center">3 (9.7%)</td>
<td valign="bottom" rowspan="3" align="center">1</td>
<td valign="bottom" align="center">3 (12.5%)</td>
<td valign="bottom" align="center">2 (7.1%)</td>
<td valign="bottom" rowspan="3" align="center">1</td>
</tr>
<tr>
<td valign="middle" align="center">Adenosquamous carcinoma</td>
<td valign="bottom" align="center">1 (1.3%)</td>
<td valign="bottom" align="center">3 (4.2%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">0 (0%)</td>
</tr>
<tr>
<td valign="middle" align="center">Squamous cell carcinoma</td>
<td valign="bottom" align="center">64 (85.3%)</td>
<td valign="bottom" align="center">64 (90.1%)</td>
<td valign="bottom" align="center">25 (78.1%)</td>
<td valign="bottom" align="center">28 (90.3%)</td>
<td valign="bottom" align="center">21 (87.5%)</td>
<td valign="bottom" align="center">26 (92.9%)</td>
</tr>
<tr>
<td valign="middle" rowspan="4" align="left">FIGO stage (n, %)</td>
<td valign="middle" align="center">I</td>
<td valign="bottom" align="center">75 (100%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" rowspan="4" align="center">&lt;0.001</td>
<td valign="bottom" align="center">32 (100%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" rowspan="4" align="center">1</td>
<td valign="bottom" align="center">24 (100%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" rowspan="4" align="center">1</td>
</tr>
<tr>
<td valign="middle" align="center">II</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">33 (46.5%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">19 (61.3%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">19 (67.9%)</td>
</tr>
<tr>
<td valign="middle" align="center">III</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">32 (45.1%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">9 (29%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">5 (17.9%)</td>
</tr>
<tr>
<td valign="middle" align="center">IV</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">6 (8.5%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">3 (9.7%)</td>
<td valign="bottom" align="center">0 (0%)</td>
<td valign="bottom" align="center">4 (14.3%)</td>
</tr>
<tr>
<td valign="middle" align="left">Age [median (IQR)]</td>
<td valign="middle" align="center"/>
<td valign="bottom" align="center">53.00 (49.00&#x2013;56.00)</td>
<td valign="bottom" align="center">55.00 (49.00&#x2013;59.00)</td>
<td valign="bottom" align="center">0.209</td>
<td valign="bottom" align="center">53.00 (48.00&#x2013; 61.75)</td>
<td valign="bottom" align="center">54.00 (48.00&#x2013;58.00)</td>
<td valign="bottom" align="center">0.549</td>
<td valign="bottom" align="center">53.50 (46.00&#x2013;57.75)</td>
<td valign="bottom" align="center">55.50 (46.75&#x2013;66.50)</td>
<td valign="bottom" align="center">0.330</td>
</tr>
<tr>
<td valign="middle" align="left">L [median (IQR)]</td>
<td valign="middle" align="center"/>
<td valign="bottom" align="center">26.00 (20.50&#x2013;31.00)</td>
<td valign="bottom" align="center">37.00 (26.50&#x2013; 45.00)</td>
<td valign="bottom" align="center">&lt;0.001</td>
<td valign="bottom" align="center">30.00 (23.00&#x2013; 34.75)</td>
<td valign="bottom" align="center">39.00 (27.00&#x2013;49.00)</td>
<td valign="bottom" align="center">&lt;0.001</td>
<td valign="bottom" align="center">28.00 (25.00&#x2013;37.75)</td>
<td valign="bottom" align="center">44.00 (34.25&#x2013; 55.25)</td>
<td valign="bottom" align="center">0.003</td>
</tr>
<tr>
<td valign="middle" align="left">SCCa [median (IQR)]</td>
<td valign="middle" align="center"/>
<td valign="bottom" align="center">1.45 (0.95&#x2013;2.73)</td>
<td valign="bottom" align="center">2.70 (1.05&#x2013;7.45)</td>
<td valign="bottom" align="center">0.007</td>
<td valign="bottom" align="center">1.15 (0.64&#x2013;2.10)</td>
<td valign="bottom" align="center">4.50 (1.35&#x2013;9.65)</td>
<td valign="bottom" align="center">&lt;0.001</td>
<td valign="bottom" align="center">2.75 (1.53&#x2013; 4.30)</td>
<td valign="bottom" align="center">5.43 (2.40&#x2013;9.59)</td>
<td valign="bottom" align="center">0.044</td>
</tr>
<tr>
<td valign="middle" align="left">Rad-score [median (IQR)]</td>
<td valign="middle" align="center"/>
<td valign="bottom" align="center">0.26 (0.21&#x2013;0.33)</td>
<td valign="bottom" align="center">0.39 (0.32&#x2013;0.51)</td>
<td valign="bottom" align="center">&lt;0.001</td>
<td valign="bottom" align="center">0.29 (0.26&#x2013;0.34)</td>
<td valign="bottom" align="center">0.41 (0.32&#x2013;0.46)</td>
<td valign="bottom" align="center">&lt;0.001</td>
<td valign="bottom" align="center">0.28 (0.23&#x2013;0.35)</td>
<td valign="bottom" align="center">0.35 (0.35&#x2013;0.41)</td>
<td valign="bottom" align="center">0.002</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>FIGO, International Federation of Gynecology and Obstetrics; IQR, interquartile range.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>US-radiomics feature extraction and selection</title>
<p>A total of 944 radiomics features were extracted from US images. There were 920 features with ICC &#x2265; 0.75, then 131 related features were obtained through univariate analysis and removed by Spearman&#x2019;s correlation analysis, and 38 imaging radiomics features were left. Finally, the following 12 features were identified as the most significant by the LASSO algorithm: wavelet.HHH_glszm_ZonePercentage, wavelet.HHH_firstorder_Mean, square_glszm_SmallAreaLowGrayLevelEmphasis, wavelet.HLL_glszm_LargeAreaHighGrayLevelEmphasis, original_glszm_ZoneEntropy, square_glcm_Correlation, wavelet.HLH_glrlm_GrayLevelVariance, wavelet.LLH_glrlm_RunLengthNonUniformityNormalized, wavelet.HLH_glcm_SumSquares, wavelet.LLH_ngtdm_Strength, wavelet.HHL_glszm_GrayLevelNonUniformity, and wavelet.LLL_ngtdm_Busyness. These were all included in the US-radiomics models.</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Clinical model construction</title>
<p>In the univariate analysis, L (p &lt; 0.001) and SCCa (p = 0.016) showed statistically significant differences between the C0 and C1 groups. The multivariate regression analysis showed that both L and SCCa were independent predictors of stage I CC.</p>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Diagnostic performance of the US-radiomics models</title>
<p>The diagnostic performance of the six radiomics models based on different ML algorithms is shown in <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>. The receiver operating characteristic (ROC) curves of these models in the training, internal validation, and external validation sets are shown in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>. Among them, the Xgboost model performed the best, with area under the curve (AUC) values in the training, internal validation, and external validation sets of 0.778, 0.751, and 0.751, respectively.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Performance of the six models in the training, internal validation, and external validation sets.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left"/>
<th valign="middle" align="left">Model</th>
<th valign="middle" align="left">AUC (95% CI)</th>
<th valign="middle" align="left">Accuracy</th>
<th valign="middle" align="left">Sensitivity</th>
<th valign="middle" align="left">Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" rowspan="6" align="left">Training set</td>
<td valign="middle" align="left">LR</td>
<td valign="middle" align="left">0.745 (0.664&#x2013;0.824)</td>
<td valign="middle" align="left">0.712</td>
<td valign="middle" align="left">0.732</td>
<td valign="middle" align="left">0.693</td>
</tr>
<tr>
<td valign="middle" align="left">DT</td>
<td valign="middle" align="left">1.000 (1.000&#x2013;1.000)</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">1</td>
</tr>
<tr>
<td valign="middle" align="left">SVM</td>
<td valign="middle" align="left">0.777 (0.702&#x2013;0.847)</td>
<td valign="middle" align="left">0.712</td>
<td valign="middle" align="left">0.775</td>
<td valign="middle" align="left">0.653</td>
</tr>
<tr>
<td valign="middle" align="left">RF</td>
<td valign="middle" align="left">0.756 (0.679&#x2013;0.831)</td>
<td valign="middle" align="left">0.712</td>
<td valign="middle" align="left">0.521</td>
<td valign="middle" align="left">0.893</td>
</tr>
<tr>
<td valign="middle" align="left">KNN</td>
<td valign="middle" align="left">0.694 (0.606&#x2013;0.771)</td>
<td valign="middle" align="left">0.685</td>
<td valign="middle" align="left">0.549</td>
<td valign="middle" align="left">0.813</td>
</tr>
<tr>
<td valign="middle" align="left">Xgboost</td>
<td valign="middle" align="left">0.778 (0.707&#x2013;0.849)</td>
<td valign="middle" align="left">0.74</td>
<td valign="middle" align="left">0.746</td>
<td valign="middle" align="left">0.733</td>
</tr>
<tr>
<td valign="middle" rowspan="6" align="left">Internal validation set</td>
<td valign="middle" align="left">LR</td>
<td valign="middle" align="left">0.756 (0.632&#x2013;0.869)</td>
<td valign="middle" align="left">0.651</td>
<td valign="middle" align="left">0.774</td>
<td valign="middle" align="left">0.531</td>
</tr>
<tr>
<td valign="middle" align="left">DT</td>
<td valign="middle" align="left">0.620 (0.509&#x2013;0.748)</td>
<td valign="middle" align="left">0.619</td>
<td valign="middle" align="left">0.677</td>
<td valign="middle" align="left">0.562</td>
</tr>
<tr>
<td valign="middle" align="left">SVM</td>
<td valign="middle" align="left">0.762 (0.636&#x2013;0.873)</td>
<td valign="middle" align="left">0.73</td>
<td valign="middle" align="left">0.903</td>
<td valign="middle" align="left">0.562</td>
</tr>
<tr>
<td valign="middle" align="left">RF</td>
<td valign="middle" align="left">0.716 (0.583&#x2013;0.835)</td>
<td valign="middle" align="left">0.683</td>
<td valign="middle" align="left">0.484</td>
<td valign="middle" align="left">0.875</td>
</tr>
<tr>
<td valign="middle" align="left">KNN</td>
<td valign="middle" align="left">0.775 (0.664&#x2013;0.885)</td>
<td valign="middle" align="left">0.746</td>
<td valign="middle" align="left">0.645</td>
<td valign="middle" align="left">0.844</td>
</tr>
<tr>
<td valign="middle" align="left">Xgboost</td>
<td valign="middle" align="left">0.751 (0.617&#x2013;0.861)</td>
<td valign="middle" align="left">0.619</td>
<td valign="middle" align="left">0.71</td>
<td valign="middle" align="left">0.531</td>
</tr>
<tr>
<td valign="middle" rowspan="6" align="left">External validation set</td>
<td valign="middle" align="left">LR</td>
<td valign="middle" align="left">0.702 (0.561&#x2013;0.840)</td>
<td valign="middle" align="left">0.635</td>
<td valign="middle" align="left">0.571</td>
<td valign="middle" align="left">0.708</td>
</tr>
<tr>
<td valign="middle" align="left">DT</td>
<td valign="middle" align="left">0.491 (0.363&#x2013;0.625)</td>
<td valign="middle" align="left">0.5</td>
<td valign="middle" align="left">0.607</td>
<td valign="middle" align="left">0.375</td>
</tr>
<tr>
<td valign="middle" align="left">SVM</td>
<td valign="middle" align="left">0.601 (0.446&#x2013;0.755)</td>
<td valign="middle" align="left">0.615</td>
<td valign="middle" align="left">0.536</td>
<td valign="middle" align="left">0.708</td>
</tr>
<tr>
<td valign="middle" align="left">RF</td>
<td valign="middle" align="left">0.743 (0.598&#x2013;0.870)</td>
<td valign="middle" align="left">0.615</td>
<td valign="middle" align="left">0.393</td>
<td valign="middle" align="left">0.875</td>
</tr>
<tr>
<td valign="middle" align="left">KNN</td>
<td valign="middle" align="left">0.544 (0.377&#x2013;0.710)</td>
<td valign="middle" align="left">0.538</td>
<td valign="middle" align="left">0.25</td>
<td valign="middle" align="left">0.875</td>
</tr>
<tr>
<td valign="middle" align="left">Xgboost</td>
<td valign="middle" align="left">0.751 (0.610&#x2013;0.880)</td>
<td valign="middle" align="left">0.731</td>
<td valign="middle" align="left">0.821</td>
<td valign="middle" align="left">0.625</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AUC, area under the curve; LR, linear regression; DT, decision tree; SVM, support vector machine; RF, random forest; KNN, K-nearest neighbor; Xgboost, eXtreme Gradient Boosting.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Clinical US-radiomics combined model</title>
<p>The combined model nomogram was established by combining the rad-score and clinical characteristics (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>). The calibration curve of the combined model all showed good agreement between the predicted and actual stage I CC in the three sets (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4B&#x2013;D</bold>
</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>
<bold>(A)</bold> The combined model nomogram. The values of clinical characteristics and rad-score can be converted into quantitative values according to the point axis. After summing the individual points to achieve the final sum shown on the total point axis, the evaluation of stage I CC is shown. <bold>(B)</bold> The calibration curve of the combined model in the training set. <bold>(C)</bold> The calibration curve of the combined model in the internal validation set. <bold>(D)</bold> The calibration curve of the combined model in the external validation set.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1353780-g004.tif"/>
</fig>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>Comparison of the three diagnostic models</title>
<p>The differential validity of the three diagnostic models (clinical, US-radiomics, and combined) is shown in <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>. The ROC curves of the three models in the training, internal validation, and external validation sets are shown in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>. The combined model had the best diagnostic performance, with AUC values in the training, internal validation, and external validation sets of 0.837, 0.828, and 0.839, respectively.</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Performance of the clinical model, US-radiomics model, and combined model in the training, internal validation, and external validation sets.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left"/>
<th valign="middle" align="left">Model</th>
<th valign="middle" align="left">AUC (95% CI)</th>
<th valign="middle" align="left">Accuracy</th>
<th valign="middle" align="left">Sensitivity</th>
<th valign="middle" align="left">Specificity</th>
<th valign="middle" align="left">p</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" rowspan="3" align="left">Training set</td>
<td valign="middle" align="left">Clinical model</td>
<td valign="middle" align="left">0.765 (0.683&#x2013;0.838)</td>
<td valign="middle" align="left">0.726</td>
<td valign="middle" align="left">0.746</td>
<td valign="middle" align="left">0.707</td>
<td valign="middle" align="left">0.001</td>
</tr>
<tr>
<td valign="middle" align="left">US-radiomics model</td>
<td valign="middle" align="left">0.778 (0.706&#x2013;0.852)</td>
<td valign="middle" align="left">0.740</td>
<td valign="middle" align="left">0.746</td>
<td valign="middle" align="left">0.733</td>
<td valign="middle" align="left">0.027</td>
</tr>
<tr>
<td valign="middle" align="left">Combined model</td>
<td valign="middle" align="left">0.837 (0.773&#x2013;0.898)</td>
<td valign="middle" align="left">0.781</td>
<td valign="middle" align="left">0.775</td>
<td valign="middle" align="left">0.787</td>
<td valign="middle" align="left">/</td>
</tr>
<tr>
<td valign="middle" rowspan="3" align="left">Internal validation set</td>
<td valign="middle" align="left">Clinical model</td>
<td valign="middle" align="left">0.802 (0.678&#x2013;0.913)</td>
<td valign="middle" align="left">0.683</td>
<td valign="middle" align="left">0.806</td>
<td valign="middle" align="left">0.562</td>
<td valign="middle" align="left">0.417</td>
</tr>
<tr>
<td valign="middle" align="left">US-radiomics model</td>
<td valign="middle" align="left">0.751 (0.617&#x2013;0.863)</td>
<td valign="middle" align="left">0.619</td>
<td valign="middle" align="left">0.710</td>
<td valign="middle" align="left">0.531</td>
<td valign="middle" align="left">0.099</td>
</tr>
<tr>
<td valign="middle" align="left">Combined model</td>
<td valign="middle" align="left">0.828 (0.713&#x2013;0.927)</td>
<td valign="middle" align="left">0.730</td>
<td valign="middle" align="left">0.806</td>
<td valign="middle" align="left">0.656</td>
<td valign="middle" align="left">/</td>
</tr>
<tr>
<td valign="middle" rowspan="3" align="left">External validation set</td>
<td valign="middle" align="left">Clinical model</td>
<td valign="middle" align="left">0.783 (0.644&#x2013;0.906)</td>
<td valign="middle" align="left">0.750</td>
<td valign="middle" align="left">0.929</td>
<td valign="middle" align="left">0.542</td>
<td valign="middle" align="left">0.130</td>
</tr>
<tr>
<td valign="middle" align="left">US-radiomics model</td>
<td valign="middle" align="left">0.751 (0.607&#x2013;0.886)</td>
<td valign="middle" align="left">0.731</td>
<td valign="middle" align="left">0.821</td>
<td valign="middle" align="left">0.625</td>
<td valign="middle" align="left">0.195</td>
</tr>
<tr>
<td valign="middle" align="left">Combined model</td>
<td valign="middle" align="left">0.839 (0.719&#x2013;0.949)</td>
<td valign="middle" align="left">0.692</td>
<td valign="middle" align="left">0.893</td>
<td valign="middle" align="left">0.458</td>
<td valign="middle" align="left">/</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AUC, area under the curve.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>The ROC curves of the three models. <bold>(A)</bold> Three models&#x2019; ROC curves in the training set. <bold>(B)</bold> Three models&#x2019; ROC curves in the internal validation set. <bold>(C)</bold> Three models&#x2019; ROC curves in the external validation.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1353780-g005.tif"/>
</fig>
</sec>
<sec id="s3_7">
<label>3.7</label>
<title>Interpretation analysis and application of the Xgboost model</title>
<p>The Shapley summary diagram in <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6A</bold>
</xref> showed the contribution of three factors (L, rad-score, and SCCa) in predicting the CC stage for each case. The greater the absolute distribution range of Shapley values, the more important for the diagnosis of the CC stage. The SHAP force plot can explain the assessment of each case, and each feature is a force for the visualized Shapley value, which either increases (positive value) or decreases (negative value) the prediction from baseline. The baseline is the mean Shapley value for all the predicted features. The length of the arrow in <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref> indicates the contribution of a feature to the Shapley value, whereas the red and blue arrows indicate positive and negative, respectively (<xref ref-type="bibr" rid="B23">23</xref>).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Xgboost model visualization and case application analysis. <bold>(A)</bold> Shapley summary diagram of the Xgboost combined model. A lower Shapley value (blue) suggests a greater tendency to stage I CC; conversely, a higher Shapley value (red) suggests a greater tendency to non-stage I CC. <bold>(B)</bold> Application analysis for two patients with CC of the Xgboost model.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-14-1353780-g006.tif"/>
</fig>
</sec>
<sec id="s3_8">
<label>3.8</label>
<title>Case application analysis of the Xgboost model</title>
<p>Two CC patients (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref>), a 53-year-old woman with stage I CC and a 47-year-old woman with stage II CC, were selected for Xgboost model analysis. The cervical lesions of patient 1 had a short length (18&#xa0;mm), low rad-score (0.214), and low SCCa (0.3 ng/mL), indicating a low SHAP value (&#x2212;2.0), which strongly suggested that this patient was stage I CC and was consistent with the final pathological results. The cervical lesions of patient 2 had a long length (46&#xa0;mm), high rad-score (0.521), and high SCCa (2.2 ng/mL), indicating a high SHAP value (1.44), which strongly suggested that this patient was non-stage I CC and was also consistent with the final pathological findings.</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>It has been studied that MRI-based radiomics can diagnose early-stage CC. The accuracy of predicting the early stage of CC pre-operatively based on MRI-radiomics was 0.684 (<xref ref-type="bibr" rid="B18">18</xref>). The AUC values of T2-weighted images (T2WI)-based and apparent diffusion coefficient (ADC)-based radiomics model for predicting the early stage of CC were 0.855 and 0.823, respectively, in the training cohort and 0.861 and 0.81, respectively, in the cohort (<xref ref-type="bibr" rid="B24">24</xref>). In our study, the AUC values for predicting stage I CC in the training, internal validation, and external validation sets were 0.837, 0.828, and 0.839, respectively. These were generally consistent with the previous studies, but they did not set up an external validation group, and MRI is sometimes limited by cost or equipment availability. Ultrasonography is currently recognized as a convenient, quick, radiation-free, and affordable examination method to help clinicians detect and diagnose CC.</p>
<p>In this study, finally, we identified 12 radiomics features from cervical US images and used them to construct predictive models of six ML classification algorithms to detect stage I CC, in which the Xgboost model performed the best. Meanwhile, we included several clinical data, and the univariate and multivariate logistic regression analyses showed that L and SCCa were independent predictors in the clinical model. SCCa is a glycoprotein secreted by squamous cell carcinoma tissue. It plays an important role in the invasion, infiltration, and metastasis of squamous carcinoma cells. It is mainly used for the diagnosis of squamous cell carcinoma. There were only 24 cases of adenocarcinoma in this study, only 11%, and the histological type was not statistically significant between the C0 and CI groups. Therefore, the influence of histological type on the results of this study can be ignored. Previous studies have also shown that SCCa level was associated with CC progression and had some significance for the prediction of CC lymphatic metastasis (<xref ref-type="bibr" rid="B25">25</xref>), which is consistent with the results of this study.</p>
<p>We constructed an explainable Xgboost combined model incorporating important clinicoradiological factors and rad-score to predict stage I CC. The combined model improved the overall prediction effect of the model compared to the clinical and US-radiomics model, with AUC values as high as 0.837, 0.828, and 0.839 in the training, internal validation, and external validation sets, respectively. The personalized contribution of each feature was visualized using the Shapley algorithm for each case, which helps to explain the predictive power of the features in this model. Furthermore, the complex Xgboost combination model was visualized as a reliable clinical diagnostic support tool that we can easily apply.</p>
<p>Furthermore, we can boldly predict the specific stage of stage I CC based on the combined model established in this study and the size of the lesion so as to plan the need for lymph node dissection. Unnecessary lymph node dissection is associated with both short- and long-term complications, such as nerve injury, lower extremity lymphedema, and lymph sac formation (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Studies had shown that none of the 161 patients with preoperative MRI showing negative pelvic lymph node status, tumor size &lt;20&#xa0;mm, and squamous/adenosquamous histotype showed LNM (<xref ref-type="bibr" rid="B28">28</xref>).</p>
<p>Of course, there are also several limitations in our study. First, the retrospective analysis was prone to selection bias. Second, the number of samples was relatively small, and the different histological types were not studied separately. Third, radiomics has reproducibility problems. This study considered the reproducibility of extracted features, the US-radiomics features were extracted from ROIs, which were delineated by two senior ultrasonologists, the extracted features were evaluated by ICC, and ICC &gt; 0.75 was considered reproducible. Meanwhile, the internal and external validation sets were set up, that is, considering the repeatability of the model. However, due to the retrospective analysis, the US images were not derived from the same machine, and the parameter settings were different, which also affected the reproducibility. This is our future research direction.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusions</title>
<p>We used the Xgboost algorithm to construct an interpretable clinical US-radiomics combined model for predicting stage I CC and used the SHAP approach to quantify the contribution of each feature to the model. The satisfactory diagnostic performance of the model was also successfully validated on the independent external validation set. Therefore, our combined model is expected to assist clinicians in evaluating stage I CC non-invasively.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Institutional Review Committee of the First Affiliated Hospital of Anhui Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants&#x2019; legal guardians/next of kin in accordance with the national legislation and institutional requirements. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article because the requirement for informed consent was waived due to the retrospective study design and use of deidentified data.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>XY: Conceptualization, Formal Analysis, Investigation, Methodology, Software, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. CG: Writing &#x2013; review &amp; editing, Formal Analysis, Software. NS: Writing &#x2013; review &amp; editing, Investigation. XQ: Investigation, Writing &#x2013; review &amp; editing, Methodology. XL: Methodology, Writing &#x2013; review &amp; editing, Formal Analysis, Software. CZ: Writing &#x2013; review &amp; editing, Conceptualization, Funding acquisition, Supervision.</p>
</sec>
</body>
<back>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the General Project of the Anhui Province Department of Science and Technology (2308085MH278).</p>
</sec>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ferlay</surname> <given-names>J</given-names>
</name>
<name>
<surname>Soerjomataram</surname> <given-names>I</given-names>
</name>
<name>
<surname>Siegel</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Torre</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Jemal</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>Ca-a Cancer J Clin</source>. (<year>2018</year>) <volume>68</volume>:<fpage>394</fpage>&#x2013;<lpage>424</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3322/caac.21492</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plagens-Rotman</surname> <given-names>K</given-names>
</name>
<name>
<surname>Polocka-Molinska</surname> <given-names>M</given-names>
</name>
<name>
<surname>Merks</surname> <given-names>P</given-names>
</name>
<name>
<surname>Gwozdzicka-Piotrowska</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kedzia</surname> <given-names>W</given-names>
</name>
<name>
<surname>Jarzabek-Bielecka</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Problems in gynaecologic oncology in girls and young women-an outline of selected issues</article-title>. <source>Clin Exp Obstet Gynecol</source>. (<year>2021</year>) <volume>48</volume>:<page-range>795&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.31083/j.ceog4804127</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>XF</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>HY</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>YY</given-names>
</name>
<name>
<surname>Sui</surname> <given-names>YX</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Cervical human papillomavirus infection, genotyping and the relationship with the results of Thinprep Cytology Test in 9174 female physical examinees in Xi'an, China</article-title>. <source>Eur J Gynaecol Oncol</source>. (<year>2021</year>) <volume>42</volume>:<page-range>537&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.31083/j.ejgo.2021.03.2196</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arbyn</surname> <given-names>M</given-names>
</name>
<name>
<surname>Weiderpass</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bruni</surname> <given-names>L</given-names>
</name>
<name>
<surname>de Sanjos&#xe9;</surname> <given-names>S</given-names>
</name>
<name>
<surname>Saraiya</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ferlay</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis</article-title>. <source>Lancet Global Health</source>. (<year>2020</year>) <volume>8</volume>:<page-range>E191&#x2013;203</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2214-109X(19)30482-6</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhatla</surname> <given-names>N</given-names>
</name>
<name>
<surname>Berek</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Fredes</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Denny</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Grenman</surname> <given-names>S</given-names>
</name>
<name>
<surname>Karunaratne</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Revised FIGO staging for carcinoma of the cervix uteri</article-title>. <source>Int J Gynecol Obstet</source>. (<year>2019</year>) <volume>145</volume>:<page-range>129&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ijgo.12749</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gien</surname> <given-names>LT</given-names>
</name>
<name>
<surname>Covens</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Lymph node assessment in cervical cancer: prognostic and therapeutic implications</article-title>. <source>J Surg Oncol</source>. (<year>2009</year>) <volume>99</volume>:<page-range>242&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jso.21199</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kocak</surname> <given-names>B</given-names>
</name>
<name>
<surname>Kus</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Kilickesmez</surname> <given-names>O</given-names>
</name>
</person-group>. <article-title>How to read and review papers on machine&#xa0;learning and artificial intelligence in radiology: a survival guide to key methodological concepts</article-title>. <source>Eur Radiol</source>. (<year>2021</year>) <volume>31</volume>:<page-range>1819&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00330-020-07324-4</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname> <given-names>V</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Basu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Berglund</surname> <given-names>A</given-names>
</name>
<name>
<surname>Eschrich</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Schabath</surname> <given-names>MB</given-names>
</name>
<etal/>
</person-group>. <article-title>Radiomics: the process and the challenges</article-title>. <source>Magnetic Resonance Imaging</source>. (<year>2012</year>) <volume>30</volume>:<page-range>1234&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mri.2012.06.010</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambin</surname> <given-names>P</given-names>
</name>
<name>
<surname>Rios-Velazquez</surname> <given-names>E</given-names>
</name>
<name>
<surname>Leijenaar</surname> <given-names>R</given-names>
</name>
<name>
<surname>Carvalho</surname> <given-names>S</given-names>
</name>
<name>
<surname>van Stiphout</surname> <given-names>R</given-names>
</name>
<name>
<surname>Granton</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Radiomics: Extracting more information from medical images using advanced feature analysis</article-title>. <source>Eur J Cancer</source>. (<year>2012</year>) <volume>48</volume>:<page-range>441&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejca.2011.11.036</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langs</surname> <given-names>G</given-names>
</name>
<name>
<surname>R&#xf6;hrich</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hofmanninger</surname> <given-names>J</given-names>
</name>
<name>
<surname>Prayer</surname> <given-names>F</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Herold</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Machine learning: from radiomics to discovery and routine</article-title>. <source>Radiologe</source>. (<year>2018</year>) <volume>58</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00117-018-0407-3</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>YY</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>HY</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Development and validation of noninvasive MRI-based signature for preoperative prediction of early recurrence in perihilar cholangiocarcinoma</article-title>. <source>J Magnetic Resonance Imaging</source>. (<year>2022</year>) <volume>55</volume>:<fpage>787</fpage>&#x2013;<lpage>802</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmri.27846</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conti</surname> <given-names>A</given-names>
</name>
<name>
<surname>Duggento</surname> <given-names>A</given-names>
</name>
<name>
<surname>Indovina</surname> <given-names>I</given-names>
</name>
<name>
<surname>Guerrisi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Toschi</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Radiomics in breast cancer classification and prediction</article-title>. <source>Semin Cancer Biol</source>. (<year>2021</year>) <volume>72</volume>:<page-range>238&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.semcancer.2020.04.002</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannini</surname> <given-names>V</given-names>
</name>
<name>
<surname>Mazzetti</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bertotto</surname> <given-names>I</given-names>
</name>
<name>
<surname>Chiarenza</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cauda</surname> <given-names>S</given-names>
</name>
<name>
<surname>Delmastro</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Predicting locally advanced rectal cancer response to neoadjuvant therapy with <sup>18</sup>F-FDG PET and MRI radiomics features</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2019</year>) <volume>46</volume>:<page-range>878&#x2013;88</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-018-4250-6</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>QQ</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>LF</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>SF</given-names>
</name>
<name>
<surname>Dou</surname> <given-names>WQ</given-names>
</name>
<etal/>
</person-group>. <article-title>Differentiating benign from Malignant renal tumors using T2-and diffusion-weighted images: A comparison of deep learning and radiomics models versus assessment from radiologists</article-title>. <source>J Magnetic Resonance Imaging</source>. (<year>2022</year>) <volume>55</volume>:<page-range>1251&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmri.27900</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tseng</surname> <given-names>PY</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>YT</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Chiu</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>YS</given-names>
</name>
<name>
<surname>Hsu</surname> <given-names>SP</given-names>
</name>
<etal/>
</person-group>. <article-title>Prediction of the development of acute kidney injury following cardiac surgery by machine learning</article-title>. <source>Crit Care</source>. (<year>2020</year>) <volume>24</volume>:<fpage>478</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13054-020-03179-9</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>MW</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>RY</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>WM</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>ZY</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>SN</given-names>
</name>
<etal/>
</person-group>. <article-title>Predicting the molecular subtype of breast cancer and identifying interpretable imaging features using machine learning algorithms</article-title>. <source>Eur Radiol</source>. (<year>2022</year>) <volume>32</volume>:<page-range>1652&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00330-021-08271-4</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>CZ</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Prediction of lymph node status in patients with early-stage cervical cancer based on radiomic features of magnetic resonance imaging (MRI) images</article-title>. <source>BMC Med Imaging</source>. (<year>2023</year>) <volume>23</volume>:<fpage>101</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12880-023-01059-6</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>BH</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>XL</given-names>
</name>
<name>
<surname>Xuan</surname> <given-names>DS</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>YW</given-names>
</name>
<etal/>
</person-group>. <article-title>Classifying early stages of cervical cancer with MRI-based radiomics</article-title>. <source>Magnetic Resonance Imaging</source>. (<year>2022</year>) <volume>89</volume>:<page-range>70&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mri.2022.03.002</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>YW</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>RF</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Qu</surname> <given-names>FY</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>XY</given-names>
</name>
<etal/>
</person-group>. <article-title>Radiomics analysis of apparent diffusion coefficient in cervical cancer: A preliminary study on histological grade evaluation</article-title>. <source>J Magnetic Resonance Imaging</source>. (<year>2019</year>) <volume>49</volume>:<page-range>280&#x2013;90</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmri.26192</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucia</surname> <given-names>F</given-names>
</name>
<name>
<surname>Visvikis</surname> <given-names>D</given-names>
</name>
<name>
<surname>Valli&#xe8;res</surname> <given-names>M</given-names>
</name>
<name>
<surname>Desseroit</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Miranda</surname> <given-names>O</given-names>
</name>
<name>
<surname>Robin</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. (<year>2019</year>) <volume>46</volume>:<page-range>864&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-018-4231-9</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiappa</surname> <given-names>V</given-names>
</name>
<name>
<surname>Bogani</surname> <given-names>G</given-names>
</name>
<name>
<surname>Interlenghi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Antisari</surname> <given-names>GV</given-names>
</name>
<name>
<surname>Salvatore</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zanchi</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Using radiomics and machine learning applied to MRI to predict response to neoadjuvant chemotherapy in locally advanced cervical cancer</article-title>. <source>Diagnostics</source>. (<year>2023</year>) <volume>13</volume>:<fpage>3139</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/diagnostics13193139</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname> <given-names>XC</given-names>
</name>
<name>
<surname>Ai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>HY</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Teng</surname> <given-names>YY</given-names>
</name>
<etal/>
</person-group>. <article-title>Noninvasive prediction of lymph node status for patients with early-stage cervical cancer based on radiomics features from ultrasound images</article-title>. <source>Eur Radiol</source>. (<year>2020</year>) <volume>30</volume>:<page-range>4117&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00330-020-06692-1</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>YT</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>XJ</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>ZW</given-names>
</name>
<etal/>
</person-group>. <article-title>Predicting the pathological invasiveness in patients with a solitary pulmonary nodule via Shapley additive explanations interpretation of a tree-based machine learning radiomics model: a multicenter study</article-title>. <source>Quantitative Imaging Med Surg</source>. (<year>2023</year>) <volume>13</volume>(<issue>12</issue>):<page-range>7828&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/qims</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>XM</given-names>
</name>
<name>
<surname>Xing</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>HB</given-names>
</name>
<etal/>
</person-group>. <article-title>Radiomics analysis based on multiparametric magnetic resonance imaging for differentiating early stage of cervical cancer</article-title>. <source>Front Med Feb</source>. (<year>2024</year>) <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmed.2024.1336640</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>ZQ</given-names>
</name>
<name>
<surname>Li</surname> <given-names>WB</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>FQ</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review</article-title>. <source>PloS One</source>. (<year>2017</year>) <volume>12</volume>:<elocation-id>e0186165</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0186165</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Achouri</surname> <given-names>A</given-names>
</name>
<name>
<surname>Huchon</surname> <given-names>C</given-names>
</name>
<name>
<surname>Bats</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Bensaid</surname> <given-names>C</given-names>
</name>
<name>
<surname>Nos</surname> <given-names>C</given-names>
</name>
<name>
<surname>L&#xe9;curu</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Complications of lymphadenectomy for gynecologic cancer</article-title>. <source>Ejso</source>. (<year>2013</year>) <volume>39</volume>:<page-range>81&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejso.2012.10.011</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantegna</surname> <given-names>G</given-names>
</name>
<name>
<surname>Petrillo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fuoco</surname> <given-names>G</given-names>
</name>
<name>
<surname>Venditti</surname> <given-names>L</given-names>
</name>
<name>
<surname>Terzano</surname> <given-names>S</given-names>
</name>
<name>
<surname>Anchora</surname> <given-names>LP</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis</article-title>. <source>BMC Cancer</source>. (<year>2013</year>) <volume>13</volume>:<fpage>127</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1471-2407-13-127</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cibula</surname> <given-names>D</given-names>
</name>
<name>
<surname>Abu-Rustum</surname> <given-names>NR</given-names>
</name>
<name>
<surname>Dusek</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zik&#xe1;n</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zaal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sevcik</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Bats AS et&#xa0;al: Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer</article-title>. <source>Gynecol Oncol</source>. (<year>2012</year>) <volume>124</volume>:<fpage>496</fpage>&#x2013;<lpage>501</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ygyno.2011.11.037</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>